Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.
Virginie NägeleAndrea KratzerGerhard ZugmaierChris HollandYoussef HijaziMax S ToppNicola GökbugetPatrick A BaeuerlePeter KuferAndreas WolfMatthias KlingerPublished in: Experimental hematology & oncology (2017)
In this study of relapsed/refractory ALL, blinatumomab-induced changes in laboratory parameters were transient and reversible. The evaluated PD markers demonstrated blinatumomab activity, and the analysis of cytokines supported the rationale for stepwise dosing. (ClinicalTrials.gov Identifier NCT01209286.).